Everest Medicines Ltd. (HK:1952)
:1952
Want to see HK:1952 full AI Analyst Report?
1952 Stock Chart & Stats
HK$51.50
-HK$1.00(-2.24%)
At close: 4:00 PM EST
HK$51.50
-HK$1.00(-2.24%)
Day’s Range― - ―
52-Week RangeHK$28.10 - HK$77.55
Previous CloseN/A
Volume6.86M
Average Volume (3M)3.13M
Market Cap
HK$10.18B
Enterprise ValueHK$8.23B
Total Cash (Recent Filing)HK$1.59B
Total Debt (Recent Filing)HK$708.72M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Sep 02, 2026EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding353,822,970
10 Day Avg. Volume4,149,807
30 Day Avg. Volume3,134,197
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)2.09
Price to Sales (P/S)6.51
P/FCF Ratio-64.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$69.50Price Target Upside34.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.68
Revenue Forecast (FY)HK$3.42B
Bulls Say, Bears Say
Bulls Say
Very Strong Revenue Growth And Healthy Gross MarginSustained ~95% YoY revenue growth alongside ~60% gross margins implies the company has achieved meaningful commercial traction and product-level economics. That combination supports durable top-line expansion and creates scope for operating leverage as fixed costs are spread over larger sales volumes.
Relatively Well-capitalized Balance SheetA sizable equity base and low debt-to-equity (~0.17) provide runway to fund ongoing operations and R&D without immediate refinancing pressure. This financial flexibility reduces short-term solvency risk and permits strategic investment during the commercial ramp.
Marked Improvement In Cash Burn Versus Prior YearMaterial reduction in operating cash outflow from 2024 to 2025 shows management progress in tightening spend and improving cash efficiency. Even though cash flow remains negative, the trend demonstrates operational discipline that can extend runway and support sustainable scaling.
Bears Say
Persistent Unprofitability And Negative Net MarginA sustained net loss and roughly -17% net margin mean earnings power has not been demonstrated. Continued unprofitability limits internal cash generation, increases reliance on capital markets, and raises execution risk until operating margins are consistently positive.
Negative Operating And Free Cash Flow RemainOngoing negative OCF and FCF, despite improvement, indicate the business is not yet self-funding. Persistent cash deficits constrain reinvestment capacity, increase refinancing risk, and may force dilutive financing or cutbacks if positive cash flow is not achieved.
Negative Returns To Shareholders HistoricallyA history of negative ROE signals that invested capital has not delivered shareholder returns and that profits have not scaled. This structural shortfall can pressure strategic choices, investor confidence, and long-term capital availability if the company cannot reverse the trend.
Everest Medicines Ltd. News
1952 FAQ
What was Everest Medicines Ltd.’s price range in the past 12 months?
Everest Medicines Ltd. lowest stock price was HK$28.10 and its highest was HK$77.55 in the past 12 months.
What is Everest Medicines Ltd.’s market cap?
Everest Medicines Ltd.’s market cap is HK$10.18B.
When is Everest Medicines Ltd.’s upcoming earnings report date?
Everest Medicines Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 86 days.
How were Everest Medicines Ltd.’s earnings last quarter?
Everest Medicines Ltd. released its earnings results on Mar 25, 2026. The company reported -HK$0.139 earnings per share for the quarter, missing the consensus estimate of HK$0.116 by -HK$0.255.
Is Everest Medicines Ltd. overvalued?
According to Wall Street analysts Everest Medicines Ltd.’s price is currently Undervalued.
Does Everest Medicines Ltd. pay dividends?
Everest Medicines Ltd. does not currently pay dividends.
What is Everest Medicines Ltd.’s EPS estimate?
Everest Medicines Ltd.’s EPS estimate is -1.08.
How many shares outstanding does Everest Medicines Ltd. have?
Everest Medicines Ltd. has 353,822,970 shares outstanding.
What happened to Everest Medicines Ltd.’s price movement after its last earnings report?
Everest Medicines Ltd. reported an EPS of -HK$0.139 in its last earnings report, missing expectations of HK$0.116. Following the earnings report the stock price went down -4.725%.
Which hedge fund is a major shareholder of Everest Medicines Ltd.?
Currently, no hedge funds are holding shares in HK:1952
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Everest Medicines Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$69.50 (34.95% Upside)
HK$69.50 (34.95% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.46%
12-Months-Change
Fundamentals
Return on Equity
-6.91%
Trailing 12-Months
Asset Growth
44.26%
Trailing 12-Months
Company Description
Everest Medicines Ltd.
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include eleven clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.
1952 Stock 12 Month Forecast
Average Price Target
HK$69.50
▲(34.95% Upside)
Technical Analysis
Zai Lab Ltd
―
Antengene Corporation Limited
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CStone Pharmaceuticals
―
Options Prices
Currently, No data available
---